SYDNEY, Australia, 16 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce its Quarterly Cash Flow report (Appendix 4C) for the quarter ended 31 March 2019.
Key Highlights this quarter include:
• First patient dosed in the Phase II HER-Vaxx (anti-HER2) study in March
• Encouraging new data from the Phase 1b trials which supports the B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer
• Positive pre-clinical data findings for KEY-Vaxx, Imugene’s PD-1 cancer vaccine, provide proof of concept and validation
• Successful Pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) provides guidance for KEY-Vaxx immunotherapy clinical development plan
• Strong financial position and well funded to progress its clinical programme
For further information please download PDF attached:
Download this document
